Synairgen's objective is the discovery and development of novel treatments for chronic respiratory disorders including asthma. Led by the world renowned Professor Stephen Holgate, the founding scientists have pioneered research into the underlying causes of respiratory diseases.
In particular, Synairgen has demonstrated that genetic make-up is critical to both the development and progression of these conditions. In doing so, potential new therapeutic targets have been identified.
|
As at 31 Dec 2012 |
IP Group holding |
IP Venture Fund* holding |
10.8% |
7.4% |
|
*IP Group has a 10%
economic interest in IP
Venture Fund |
Holdings represent undiluted beneficial equity interest excluding debt